[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100413706":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":32,"locations":43,"responsibleParty":220,"collaborators":222,"id":226,"slug":227,"hasResults":228,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":228,"sex":234,"minAge":235,"maxAge":236,"enrollmentInfo":237,"targetDuration":26,"studyType":240,"phases":241,"briefSummary":243,"conditions":244,"keywords":26,"overallStatus":46,"whyStopped":26,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":255},{"fullName":5,"class":6},"Fondation Ophtalmologique Adolphe de Rothschild","NETWORK",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cangrelor group","EXPERIMENTAL","treated by P2Y12 inhibitor (cangrelor) in addition to MT and BMM. The dose of cangrelor will be started with a 30 micrograms\u002Fkg IV bolus over 1 minute right after randomization and before MT. The bolus will be immediately followed with 4 micrograms\u002Fkg\u002Fmin IV infusion for the duration of MT up to 4 hours. Cangrelor infusion will be stopped at the end of the MT procedure and will not go further 4 hours. Transition to oral antiplatelet therapy will be possible 1 hour after cangrelor infusion discontinuation. No other anti-thrombotic drug is authorized during cangrelor infusion. MT technique choice is left to the investigator decision.",[13],"Drug: Cangrelor",{"label":15,"type":16,"description":17,"interventionNames":18},"Best medical management group","ACTIVE_COMPARATOR","treated by BMM associated to MT. Anti-thrombotic including alteplase are authorized if they follow the recommendations of the international guidelines. If alteplase infusion is given, no other anti-thrombotic drug is allowed for the following 24 hours. MT technique choice is left to the choice of the investigator.",[19],"Other: best medical management",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Cangrelor","administration of cangrolor by iv befor thrombectomy",[9],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"OTHER","best medical management","used yhe best medical management",[15],[33,39],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},"Mikael Pr MAZIGHI, Pr","CONTACT","01 48 03 65 65","+ 33","mmazighi@for.paris",{"name":40,"role":35,"phone":41,"phoneExt":37,"email":42},"Amélie YAVCHITZ, MD, PhD","01 48 03 64 54","ayavchitz@for.paris",[44,62,75,88,102,116,130,144,158,169,178,192,206],{"facility":45,"status":46,"city":47,"state":26,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"CHU de Besançon","RECRUITING","Besançon","25030","France","FR",{"type":52,"coordinates":53},"Point",[54,55],6.01815,47.24878,{"lat":55,"lon":54},[58],{"name":59,"role":35,"phone":60,"phoneExt":37,"email":61},"Guillaume, MD, PhD","03 81 66 89 37","guillaume.charbonnier@univ-fcomte.fr",{"facility":63,"status":46,"city":64,"state":26,"zip":26,"country":49,"countryCode":50,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"Hôpital Pellegrin (CHU de Bordeaux)","Bordeaux",{"type":52,"coordinates":66},[67,68],-0.58046,44.84124,{"lat":68,"lon":67},[71],{"name":72,"role":35,"phone":73,"phoneExt":37,"email":74},"Gaultier MARNAT, MD","05 56 79 56 79","gaultier.marnat@chu-bordeaux.fr",{"facility":76,"status":46,"city":77,"state":26,"zip":78,"country":49,"countryCode":50,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Hospices civils de Lyon, Hôpital Pierre Wertheimer","Bron","69500",{"type":52,"coordinates":80},[81,82],4.91303,45.73865,{"lat":82,"lon":81},[85],{"name":86,"role":35,"phone":26,"phoneExt":37,"email":87},"Tae-Hee CHO, MD","tae-hee.cho@chu-lyon.fr",{"facility":89,"status":46,"city":90,"state":26,"zip":91,"country":49,"countryCode":50,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"Hôpital Salengro (CHU Lille)","Lille","59037",{"type":52,"coordinates":93},[94,95],3.05512,50.63391,{"lat":95,"lon":94},[98],{"name":99,"role":35,"phone":100,"phoneExt":37,"email":101},"Lucie DELLA SCHIAVA, MD","03 20 44 59 62","Lucie.DELLASCHIAVA@CHRU-LILLE.FR",{"facility":103,"status":46,"city":104,"state":26,"zip":105,"country":49,"countryCode":50,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Hôpital Dupuytren (CHU Limoges)","Limoges","87000",{"type":52,"coordinates":107},[108,109],1.24759,45.83362,{"lat":109,"lon":108},[112],{"name":113,"role":35,"phone":114,"phoneExt":37,"email":115},"Aymeric ROUCHAUD, Pr","05 55 05 55 55","AYMERIC.ROUCHAUD2@chu-limoges.fr",{"facility":117,"status":46,"city":118,"state":26,"zip":119,"country":49,"countryCode":50,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"CHU La Timone","Marseille","13005",{"type":52,"coordinates":121},[122,123],5.38107,43.29695,{"lat":123,"lon":122},[126],{"name":127,"role":35,"phone":128,"phoneExt":37,"email":129},"Laurent SUISSA, MD-PhD","04 91 38 58 75","laurent.suissa.@ap-hm.fr",{"facility":131,"status":46,"city":132,"state":26,"zip":133,"country":49,"countryCode":50,"cosmosGeoPoint":134,"geoPoint":138,"contacts":139},"Hôpital Central (CHU de Nancy)","Nancy","54000",{"type":52,"coordinates":135},[136,137],6.18496,48.68439,{"lat":137,"lon":136},[140],{"name":141,"role":35,"phone":142,"phoneExt":37,"email":143},"Benjamin GORY, Pr","03 83 85 95 27","b.gory@chru-nancy.fr",{"facility":145,"status":46,"city":146,"state":26,"zip":147,"country":49,"countryCode":50,"cosmosGeoPoint":148,"geoPoint":152,"contacts":153},"Hôpital Lariboisière AP-HP","Paris","75010",{"type":52,"coordinates":149},[150,151],2.3488,48.85341,{"lat":151,"lon":150},[154],{"name":155,"role":35,"phone":156,"phoneExt":37,"email":157},"Alexis, GUEDON","01 49 95 81 17","alexis.guedon@aphp.fr",{"facility":159,"status":46,"city":146,"state":26,"zip":160,"country":49,"countryCode":50,"cosmosGeoPoint":161,"geoPoint":163,"contacts":164},"Hôpital Pitié-Salpêtrière AP-HP","75013",{"type":52,"coordinates":162},[150,151],{"lat":151,"lon":150},[165],{"name":166,"role":35,"phone":167,"phoneExt":37,"email":168},"Charlotte Rosso, Pr","01 42 16 18 54","charlotte.rosso@aphp.fr",{"facility":170,"status":46,"city":146,"state":26,"zip":171,"country":49,"countryCode":50,"cosmosGeoPoint":172,"geoPoint":174,"contacts":175},"Hôpital Fondation A de Rothschild","75019",{"type":52,"coordinates":173},[150,151],{"lat":151,"lon":150},[176],{"name":177,"role":35,"phone":36,"phoneExt":37,"email":38},"Mikael MAZIGHI, Pr",{"facility":179,"status":46,"city":180,"state":26,"zip":181,"country":49,"countryCode":50,"cosmosGeoPoint":182,"geoPoint":186,"contacts":187},"CHU de Strasbourg","Strasbourg","67200",{"type":52,"coordinates":183},[184,185],7.74553,48.58392,{"lat":185,"lon":184},[188],{"name":189,"role":35,"phone":190,"phoneExt":37,"email":191},"Raoul POP","03 88 12 27 87","raoul.pop@chu-strasbourg.fr",{"facility":193,"status":46,"city":194,"state":26,"zip":195,"country":49,"countryCode":50,"cosmosGeoPoint":196,"geoPoint":200,"contacts":201},"Hôpital Foch","Suresnes","92150",{"type":52,"coordinates":197},[198,199],2.22929,48.87143,{"lat":199,"lon":198},[202],{"name":203,"role":35,"phone":204,"phoneExt":37,"email":205},"Bertrand LAPERGUE, MD","01 46 25 59 73","b.lapergue@hopital-foch.com",{"facility":207,"status":46,"city":208,"state":26,"zip":209,"country":49,"countryCode":50,"cosmosGeoPoint":210,"geoPoint":214,"contacts":215},"Hôpital Purpan (CHU de Toulouse)","Toulouse","31300",{"type":52,"coordinates":211},[212,213],1.44367,43.60426,{"lat":213,"lon":212},[216],{"name":217,"role":35,"phone":218,"phoneExt":37,"email":219},"Lionel CALVIERE, MD","05 61 77 94 86","calviere.l@chu-toulouse.fr",{"type":221,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[223],{"name":224,"class":225},"Ministry of Health, France","OTHER_GOV","100413706","phase-3-reperfusion-with-p2y12-inhibitors-in-addition-to-mechanical-thrombectomy-for-perfusion-imaging-selected-acute-stroke-patients-100413706",false,"NCT04667078","REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts","REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts (REPERFUSE)","REPERFUSE","Inclusion Criteria:\n\n* Age 18 or older\n* Anterior circulation intracanial large artery occlusion isolated (Intracranial ICA and\u002For MCA) proved on CTA or MRA.\n* Symptoms onset \\\u003C 24h at imaging\n* Indication for MT and fulfillment of the following brain imaging criteria :\n\n  1. Perfusion imaging: An initial infarct volume (ischemic core on DWI or CTP calculated by the RAPID software) of less than 70 ml, a ratio between the critically hypoperfused lesion volume (calculated by RAPID with a TMax\\>6s) and initial infarct volume of 1.8 or more, and an absolute difference between those 2 volumes of 15 ml or more.\n\n     OR (if perfusion imaging not available or uninterpretable) :\n  2. CORE CLINICAL MISMATCH: Core calculated on DWI by RAPID, \\\u003C25 mL if NIHSS 6-20 and \\\u003C50 mL if NIHSS\\>20\n\n     OR (if RAPID results are not considered reliable by the clinician) :\n  3. CORE CLINICAL MISMATCH according to the clinician evaluation\n* Pre-stroke mRS ≤ 2\n* NIHSS ≥ 6\n\nExclusion Criteria:\n\n* Contraindication to MT\n* Patient over 80 years old with \\>10 microbleeds on pre-treatment MRI\n* Pre-existing dependency with mRS ≥3.\n* Known tandem ICA-MCA occlusions requiring stenting\n* ASPECT\\\u003C6 on NCCT or DWI-MRI\n* Known hypersensitivity to cangrelor or to any of the excipients (mannitol, sorbitol)\n* History of previous intracranial hemorrhage\n* Evidence of active bleeding or acute trauma (fracture) on examination\n* Recent surgery with a significant risk of bleeding\n* VKA oral anticoagulation with INR \\>1.7\n* Curative heparin or direct oral anticoagulants (DOACs) in previous 48 hours with specific DOAC dosage ≥50 ng\u002Fml and abnormal thrombin time for patients on dabigatran or abnormal specific anti-Xa activity for patients on apixaban, edoxaban, or rivaroxaban\n* Platelet count \\\u003C100 000\u002F mm3\n* Woman of childbearing age without a pregnancy test or with a positive serum pregnancy test\n* Patient benefiting from a legal protection\n* Non-membership of a national insurance scheme\n* Opposition of the patient or (in case of inclusion as a matter of urgency) of the trustworthy person\n* Participation in another study regarding AIS care interfering with this study.","ALL","18 Years","80 Years",{"count":238,"type":239},368,"ESTIMATED","INTERVENTIONAL",[242],"PHASE3","The main objective is to evaluate the efficacy of IV administration of the P2Y12 inhibitor (cangrelor) in addition to mecanich thrombectomy and WMD versus mecanich thrombectomy and WMD alone on the functional prognosis at 3 months, in patients with acute ischemic stroke eligible for mecanich thrombectomy on the basis of infusion imaging between 0 and 24 hours after the onset of symptoms.",[245],"Acute Ischemia","2026-02-27",{"date":248,"type":249},"2026-03-02","ACTUAL",{"date":251,"type":249},"2022-03-02",{"date":253,"type":239},"2030-09-01",{"name":5,"class":6},13]